Org. age Ohio . 711 - The Ohio State University

40
Otterson GA, Lavelle J, Villalona-Calero MA, Shah M, Wei X, Chan KK, Fischer B, and Grever M. A Phase I
clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid
tumors. Invest New Drugs 23(6):555-562, 2005.
Xiao JJ, Huang Y, Dai Z, Liu S, Chen J, Covey JM, Wright JM, Byrd J, Marcucci G, Sadée W and Chan KK.
Chemo-resistance to depsipeptide FK228 is mediated by reversible MDR1 induction in human cancer cell lines.
Journal of Pharmacology and Experimental Therapeutics 314(1):467-475, 2005.
Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Wickham J, Davis ME, Lucas
DM, Fischer B, Shank R, Binkley B, Wright J, Chan KK, and Grever MR. A phase 1 study of Depsipeptide
(FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105: 959-967, 2005.
Liu Z, Floss HG, Cassady JM, and Chan KK. Metabolism studies of the anti-tumor gent maytansine and its
analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry. J Mass Spectrom. 40: 389-399,
2005.
Huang Y, Blower PE, Yang C, Barbacioru C, Dai Z, Zhang Y, Xiao JJ, Chan KK, and Sadée W. Correlating gene
expression with chemical scaffolds of cytotoxic agents: ellipticines as substrates and inhibitors of MDR1. The
Pharmacogenomics Journal 5:112-125, 2005.
Liu Z, Chan KK, and Wang JJ. Tandem mass spectrometric analysis of cyclophosphamide, ifosfamide and their
metabolites. Rapid Commun Mass Spectrom, 19 (18): 2581-2590, 2005.
Dai G, Wei X, Liu Z, Liu S, Marcucci G, and Chan KK. Characterization and quantification of Bcl-2 antisense
G3139 and metabolites in plasma and urine by ion-pair reversed phase HPLC coupled with electrospray ion-trap
mass spectrometry. J Chromatog B, 825 (2): 201-213, 2005.
Dai G, Chan KK, Shen TS, Hoyt D, Klisovic M, Caliguri MA, Byrd J, Grever M, and Marcucci, G. Cellular
uptake and intracellular levels of the Bcl-2 antisense G3139 in cultured cells and treated patients with acute
myeloid leukemia. Clinical Cancer Research, 11(8): 2998-3008, 2005.
Xiao JJ, Foraker AB, Swaan PW, Liu S, Huang Y, Dai Z, Chen J, Sadee W, Byrd J, Marcucci G, and Chan KK.
Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and Multidrug
Resistance-Associated Protein 1. J Pharmacol Exp Thera. 313(1): 268-276, 2005.
Miller DD, Brueggemeier RW, and Dalton JT. Adrenocorticoids. In: Principles of Medicinal Chemistry, 5th
Edition. Foye WO, Lemke Tl, and Williams DA (Eds.), Williams and Wilkins, Baltimore, MD.
Miller DD, Brueggemeier RW, and Dalton JT. Men's Health. In: Principles of Medicinal Chemistry, 5th Edition.
Foye WO, Lemke Tl, and Williams DA (Eds.), Williams and Wilkins, Baltimore, MD.
Bohl CE, Miller DD, Chen J, Bell CE, and Dalton JT. Structural Basis for Accomodation of Nonsteroidal
Ligands in the Androgen Receptor. Journal of Biological Chemistry, 280(45):37747-37754, 2005.
Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT. Structural Basis for Antagonism and Resistance of
Bicalutamide in Prostate Cancer. Proc Natl Acad Sci U S A. 102(17): 6201-6206, 2005.
Chen J, Kim J, and Dalton JT. Discovery and Therapeutic Promise of Selective Androgen Receptor Modulators.
Molecular Interventions, 5(3):173-188, 2005.
Phelps MA, Foraker AB, Gao W, Dalton JT, Swaan PW. A novel rhodamine-riboflavin conjugate probe exhibits
distinct fluorescence resonance energy transfer that enables riboflavin trafficking and subcellular localization
studies. Molecular Pharmaceutics, 1(4):257-66, 2005.
Chen J, Hwang DJ, Chung K, Bohl CE, Fisher SJ, Miller DD, Dalton JT. In vitro and in vivo structure-activity
relationships of novel androgen receptor ligands with multiple substituents in the B-ring. Endocrinology,
146(12):5444-54, 2005.
Nair V, Mustafa SM, Mohler ML, Fisher SJ, Dalton JT, and Miller DD. Synthesis of irreversibly binding
bicalutamide analogs for imaging studies. Tetrahedron Letters, 46:4821-4823, 2005.